Maintenance Options in Patients With Bladder Cancer

Chandler H. Park, MD, discusses real-world data for maintenance avelumab in bladder cancer and factors that sway his treatment selection.

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Chandler H. Park, MD, discusses NCCN treatment regimens for patients with metastatic bladder cancer.

Petros Grivas, MD, PhD, discusses how the JAVELIN Bladder 100 trial established avelumab as standard maintenance therapy for advanced bladder cancer.